These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1806765)

  • 21. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
    Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
    Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
    Gold HK; Yasuda T; Jang IK; Guerrero JL; Fallon JT; Leinbach RC; Collen D
    Circulation; 1991 Jun; 83(6 Suppl):IV26-40. PubMed ID: 2040069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis.
    Pratico D; Murphy NP; Fitzgerald DJ
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1178-85. PubMed ID: 9190851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.
    Kerins DM; Shuh M; Kunitada S; Fitzgerald GA; Fitzgerald DJ
    J Pharmacol Exp Ther; 1991 Apr; 257(1):487-92. PubMed ID: 1708425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
    Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
    J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
    Fitzgerald DJ; Wright F; FitzGerald GA
    Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
    Fitzgerald DJ; Fitzgerald GA
    Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7585-9. PubMed ID: 2508092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
    Haskel EJ; Adams SP; Feigen LP; Saffitz JE; Gorczynski RJ; Sobel BE; Abendschein DR
    Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Coronary thrombosis--an old concept in a new light].
    Baur HR
    Schweiz Rundsch Med Prax; 1992 Sep; 81(39):1147-51. PubMed ID: 1410998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.
    Yao SK; McNatt J; Anderson HV; Eidt J; Cui KX; Golino P; Glas-Greenwalt P; Maraganore J; Buja LM; Willerson JT
    Am J Physiol; 1992 Feb; 262(2 Pt 2):H374-9. PubMed ID: 1539695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ; Connolly TM; York SJ; Bush LR
    Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
    Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti thrombotic therapy after coronary thrombolysis].
    Tani S; Kanmatsuse K
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():484-8. PubMed ID: 12735020
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
    Saito T; Saitoh S; Asakura T; Kanke M; Owada K; Maruyama Y
    Int J Cardiol; 1993 Mar; 38(3):225-33. PubMed ID: 8463004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
    Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.